Skip to content

Assessment and improvement of regional citrate anticoagulation in continuous renal replacement therapy

Assessment and improvement of regional citrate anticoagulation in continuous renal replacement therapy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025052
Enrollment
Unknown
Registered
2019-08-09
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Case series:regional citrate anticoagulation

Sponsors

The Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients are informed with informed consent form; 2. Aged 20 to 80 years; 3. Meet one of the five following requirements: (1) Maintainance hemodialysis patients with dialysis age > 3 months and has a sufficient blood flow; (2) Patients diagnosed with RIFLE-Fc or RIFLE-Fu; (3) Patients diagnosed with renal failure together with hepatic insufficiency; (4) Patients diagnosed with MODS.

Exclusion criteria

Exclusion criteria: 1. Patients were treated with medicine containing citrate in the last week; 2. Patients were treated with blood, plasma, or platelet in the last 48 hours; 3. Alkalosis PH > 7.55; 4. Severe lactic acidosis; 5. Patients are estimated to live less than 48 hour; 6. Other factors.

Design outcomes

Primary

MeasureTime frame
bone turnover;

Countries

China

Contacts

Public ContactFeng Ding

The Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine

dingfeng@sjtu.edu.cn+86 18919790062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026